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A B S T R A C T
In the present study we investigated the association of the RANTES (regulated upon activation,
normal T-cell expressed and secreted) −28C > G and −403G > A promoter polymorphisms with
the concentration of serum RANTES and CAD (coronary artery disease) in Korean men. We
included 553 male CAD patients with (n= 176) or without (n= 377) Type 2 diabetes, aged 40–
65 years with previous myocardial infarction (∼50%) or angiographically confirmed CAD (∼50%),
and 416 aged-matched healthy male controls. The main outcome measures were the OR (odds
ratio) of CAD risk and the serum RANTES concentration evaluated by sandwich ELISA. Although
the RANTES −28C > G genotype had no significant association with CAD risk, the presence
of the minor allele of the RANTES −403G > A single nucleotide polymorphism was associated
with a lower risk of CAD {OR 0.70 [95% CI (confidence interval) 0.54–0.92], P= 0.011} after
adjusting for age, BMI (body mass index), cigarette smoking and alcohol consumption. Serum
RANTES concentrations were significantly associated with the −403G > A genotype in controls
(G/G: 44.7 +− 3.3 ng/ml, G/A: 36.5 +− 2.0 ng/ml, A/A: 28.7 +− 2.5 ng/ml; P< 0.001), non-diabetic
CAD patients (G/G: 50.9 +− 3.0 ng/ml, G/A: 42.2 +− 2.6 ng/ml, A/A: 41.3 +− 4.4 ng/ml; P< 0.05)
and diabetic CAD patients (G/G: 58.5 +− 3.5 ng/ml, G/A: 49.6 +− 4.1 ng/ml, A/A: 42.2 +− 4.3 ng/ml;
P< 0.05); however, such associations were not observed in the subgroup of CAD patients taking
lipid-lowering medication. Moreover, serum RANTES was positively correlated with C-reactive
protein (r= 0.289, P< 0.001) and platelet counts (r= 0.253, P< 0.001). The results of the present
study demonstrate that the RANTES −403A allele is associated with lower serum RANTES
concentrations and consequently with reduced CAD risk.
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INTRODUCTION
Inflammation is emerging as a significant promoter of
the initiation and progression of atherosclerotic lesion
formation [1]. RANTES (regulated upon activation,
normal T-cell expressed and secreted) is a CC chemokine,
generated by circulatory lymphocytes and some types of
tissue cell monocytes, that plays an important role in the
inflammatory process [2]. RANTES has been implicated
in two key initial stages of the atherosclerotic process:
chemoattraction of leucocytes to the endothelial wall
and induction of leucocyte transendothelial migration.
This concept is supported by the protective effect seen
following the blockage of RANTES receptors in ApoE
(apolipoprotein E)-deficient mice [3], suggesting that
RANTES levels affect the progress of atherogenesis
through the inflammatory pathway.
RANTES is coded by the CCL5 gene that has been
localized to the region q11.2–q12 of chromosome 17. Two
SNPs (single nucleotide polymorphisms) of −28C>G
and −403G>A in the RANTES promoter region have
been shown to have a possible association withRANTES
gene expression [4–6]. Previously, Simeoni et al. [7] have
reported that the A allele at the RANTES −403G>A
promoter polymorphism was associated with increased
acute coronary syndrome, independent of conventional
CAD (coronary artery disease) risk factors. However,
a phenotype associated with polymorphic sites in the
RANTES promoter has not definitely been determined,
due to the complex nature of RANTES gene expression.
Therefore in the present study our goal was to examine
the association of RANTES −28C>G and −403G>A
promoter polymorphisms with the serum RANTES
concentration and CAD in Korean male participants in
a Yonsei University Hospital Cardiovascular Genome
Center case-control study. Moreover, we investigated the
correlation of serumRANTES levels with platelet counts




In the present study, we included 553 consecutive CAD
patients and 416 healthy controls from an ethnically and
geographically homogenous Korean population.
MaleCADpatientswith (n= 176) orwithout (n= 377)
Type 2 diabetes, admitted to the Cardiovascular Center,
Yonsei University Severance Hospital, Seoul, South
Korea, were recruited. The inclusion criteria were:
(i) aged 40–65 years, (ii) angiographic evidence with
50%occlusionof oneormoremajor coronary arteryor
previousMI (myocardial infarction) confirmed according
to the WHO (World Health Organization) criteria for
symptoms, enzyme elevation or electrocardiographic
changes, (iii) absence of non-atherogenic occlusion,
such as osteal stenosis and spasm, and (iv) no
orthopaedic limitations, no extreme weight loss or gain
over the previous 6 months, or any diagnosis of liver
disease, renal disease and thyroid or pituitary disease. The
inclusion criteria for the healthy male control subjects
(n= 416) included: aged 40–65 years, no history or dia-
gnosis of atherosclerosis, vascular disease, diabetes mel-
litus, cancer (clinically or by anamnesis) or renal disease
and no pathological ECG patterns. None of the healthy
male subjects were taking medication. Written informed
consent was obtained from all subjects. The study pro-
tocol complied with the Guidelines for Genome/Genetic
Research issued by the Korean government and was
approved by the Institute of Review Board of Yonsei




Body weight and height were measured unclothed and
without shoes in the morning. BMI (body mass index)
was calculated as body weight in kilograms divided by
height in metres square (kg/m2). Blood pressure was
determined from the left arm of seated patients with an
automatic bloodpressuremonitor (TM-2654;A&D) after
20 min of rest. The average of three measurements was
recorded for each subject.
Venous blood specimens were collected in EDTA-
treated and plain tubes between 08.00 hours and
10.00 hours after an overnight fast. The tubes were
immediately covered with aluminum foil and placed on
ice until they arrived at the laboratory. EDTA-treated
whole blood was immediately used for a complete blood
cell count, and serumwas withdrawn after centrifugation
for 30 min at 1230 g at 4 ◦C and then aliquots were stored
at −70 ◦C until analysis. Serum taken from plain tubes
was used for analysing all metabolic variables (including
RANTES levels) in the present study.
Genotyping of the RANTES − 28C>G and
− 403G> A polymorphisms
Genomic DNA was prepared from peripheral blood
samples using a Puregene® DNA purification kit
(Gentra), following the manufacturer’s protocol.
RANTES SNPs −28C>G (rs2280788) and −403G>A
(rs2107538) were genotyped using the TaqMan fluoro-
genic 5′ nuclease assay (Applied Biosystems). The final
volume of PCR was 5 µl, which contained 2 ng of gen-
omic DNA and 2.5 µl of TaqMan Universal PCRMaster
Mix, with 0.125 µl of 40× Assay Mix or 0.25 µl of 20×
Assay Mix. Thermal cycling conditions were as follows:
50 ◦C for 2 min to activate the uracil N-glycosylase and
to prevent carry-over contamination, 95 ◦C for 10 min
to activate the DNA polymerase, followed by 40 cycles
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of 92 ◦C for 15 s and 60 ◦C for 1 min. All PCRs were
performed using 384-well plates by a Dual 384-well
GeneAmp PCR System 9700 (Applied Biosystems), and
the end point fluorescent readings were performed on an
ABIPrism7900HTSequenceDetection System (Applied
Biosystems). Duplicate samples and negative controls
were included to ensure accuracy of genotyping.
Serum lipid profiles, glucose and insulin
Fasting serum concentrations of total cholesterol
and triacylglycerols (triglycerides) were measured
using commercially available kits on a Hitachi 7150
Autoanalyser. After using dextran sulfate magnesium
to precipitate serum chylomicron, LDL (low-density
lipoprotein) and VLDL (very LDL), the remaining
HDL (high-density lipoprotein) cholesterol from the
supernatant was measured by an enzymatic method.
LDL cholesterol was indirectly estimated in subjects
with serum triacylglycerol concentrations <4.52 mol/l
(400 mg/ml) using the Friedewald formula. In subjects
with serum triacylglycerol concentrations 4.52 mol/l,
LDL cholesterol was measured directly using an
enzymatic method on a Hitachi 7150 Autoanalyser.
Fasting glucose was measured by the glucose oxidase
method using a Beckman Glucose Analyser (Beckman
Instruments). Insulinwasmeasured using a commercially
available RIA (Immuno-Nucleo Corporation).
Circulating levels of CRP and RANTES, and
platelet count
Serum CRP concentrations were measured with an
Express plus autoanalyser (Chiron Diagnostics) using
an hs-CRP-Latex (II) X2 kit (Seiken Laboratories) that
allowed detection of CRP concentrations as low as
0.001 mg/dl and as high as 32 mg/dl. The intra- and
inter-assay coefficients of variation of CRP were 1.3%
and 1.5% respectively. The platelet count was measured
using an electric resistance method using an automatic
Blood Cell Counter (LC-240A; Horiba). The intra- and
inter-assay coefficients of variation of platelet counts
were 1.7% and 1.9% respectively. The serum RANTES
level was measured, in duplicate, using an ELISA (R&D
Systems) according to the manufacturer’s protocol. The
resultant colour reaction was read using a Victor2
plate reader (PerkinElmer) at 450 nm and wavelength
correction was set to 540 nm. The intra- and inter-
assay coefficients of variation of RANTES were 2.9%
and 6.4% respectively and the analytical sensitivity was
6.0 pg/ml.
Statistical analysis
Statistical analyses were performed with SPSS version
12.0 for Windows. HWE (Hardy–Weinberg equili-
brium) and LD (linkage disequilibrium) were examined
using the Executive SNP Analyzer 1.2A (http://snp.
istech.info/snp/SNPAnalyzer.html). The association
between CAD and genotype was calculated using the
OR (odds ratio) [95% CIs (confidence intervals)] of
a χ 2 test and a logistic regression analysis with an
adjustment for age, BMI, smoking and drinking status.
An independent Student’s t test with a general linear
model followed by a Tukey’s test was used to compare
the differences between controls and CAD patients
and among genotype group within controls and CAD
patients. ANOVA followed by Tukey’s test was also used
to compare the differences among genotype groups in
control subjects and CAD patients. Pearson correlation
test was used to examine the relationship between
RANTES concentrations and other biomarkers. Each
variable was examined for normal distribution patterns.
Significantly skewed variables were log-transformed.
For descriptive purposes, mean values are presented
using untransformed and unadjusted values. Results
are expressed as means+− S.E.M. A two-tailed value of
P< 0.05 was considered statistically significant.
RESULTS
Clinical features of control subjects and CAD patients
are shown in Table 1. Case patients were older
(P= 0.032) and heavier (P= 0.014) than controls. Case
patients had a lower prevalence of current smoking
and alcohol drinking. Case patients had lower total
and LDL cholesterol, probably because about two
thirds of them (n= 353) had been treated with LLD
(lipid-lowering drug) therapy. About one third of case
patients had Type 2 diabetes, thus we subdivided CAD
patients into two groups: those with or without Type 2
diabetes. CAD patients without Type 2 diabetes were
treated with lipid-lowering (66.5%), antihypertensive
(94.1%) or antiplatelet (96.0%) drugs. Likewise, CAD
patients with Type 2 diabetes were treated with LLDs
(58.5%), antihypertensive (97.7%), antiplatelet (97.2%)
or hypoglycaemic (61.9%) drugs. Case patients had
higher levels of glucose, insulin, triacylglycerol, platelet
counts, RANTES and CRP than controls before and
after adjustment for age, BMI, cigarette smoking
and alcohol drinking. The subgroup of CAD patients
with diabetes showed higher levels of glucose, triacyl-
glycerol, total cholesterol and RANTES than those
without diabetes.
Distribution of RANTES promoter
− 28C>G and − 403G> A gene
polymorphisms
Genotype distributions were in HWE in the entire
population as well as when patients and controls were
separated. The relative −403G>A genotype and allele
frequencies in all patients or in the subgroup of CAD
patients with or without diabetes differed significantly
C© The Authors Journal compilation C© 2007 Biochemical Society
352 Y. Jang and others
Table 1 Baseline characteristics of healthy controls and CAD patients with or without Type 2 diabetes
Values are means+− S.E.M. or percentages. §Values are log-transformed. ∗P < 0.05, ∗∗P < 0.01 and ∗∗∗P < 0.001 compared with controls; †P < 0.05 and
††P < 0.001 compared with CAD patients without Type 2 diabetes with adjustment for age, BMI, cigarette smoking and alcohol consumption status. BP, blood
pressure.
CAD patients
Controls All Without Type 2 diabetes With Type 2 diabetes
(n = 416) (n = 553) (n = 377) (n = 176)
Age (years) 53.8+− 0.34 54.8+− 0.29∗ 54.6+− 0.35 55.1+− 0.52∗
BMI (kg/m2) 24.6+− 0.13 25.0+− 0.11∗ 25.0+− 0.13∗ 25.2+− 0.24∗
Cigarette smoker (%) 28.7 21.1∗∗ 19.7∗ 24.1
Alcohol drinker (%) 74.1 64.4∗∗ 65.8∗ 61.5∗∗
Systolic BP (mmHg) 127.4+− 0.82 126.5+− 0.76 124.0+− 0.86∗∗∗ 131.9+− 1.40∗††
Diastolic BP (mmHg) 81.9+− 0.53 79.8+− 0.42∗∗∗ 79.5+− 0.48∗∗∗ 80.5+− 0.81
Glucose (mg/dl) 93.6+− 0.60 104.6+− 1.51∗∗∗ 88.6+− 0.58∗∗∗ 139.0+− 3.33∗∗∗††
Insulin (µ-units/ml)§ 8.36+− 0.18 10.4+− 0.22∗∗∗ 10.3+− 0.22∗∗∗ 10.5+− 0.50∗∗∗
Triacylglycerol (mg/dl)§ 137.0+− 3.51 147.9+− 2.91∗∗∗ 142.4+− 3.47∗ 159.9+− 5.20∗∗∗††
Total cholesterol (mg/dl) 196.5+− 1.68 177.9+− 1.71∗∗∗ 175.8+− 1.98∗∗∗ 182.6+− 3.25∗∗∗†
LDL cholesterol (mg/dl) 118.1+− 1.62 101.4+− 1.53∗∗∗ 101.4+− 1.79∗∗∗ 101.4+− 2.92∗∗∗
HDL cholesterol (mg/dl) 49.0+− 0.63 44.6+− 0.49∗∗∗ 44.3+− 0.59∗∗∗ 45.3+− 0.90∗
Antidyslipidaemic therapy (%) – 63.9 66.5 58.5
Antihypertensive therapy (%) – 95.3 94.1 97.7
Antiplatelet therapy (%) – 96.4 96.0 97.2
Hypoglycaemic therapy (%) – 19.8 0 61.9††
Platelet count (×103/µl)§ 237.6+− 2.82 245.6+− 2.58 246.8+− 3.01∗ 243.1+− 4.92
RANTES (ng/ml)§ 37.7+− 1.56 48.6+− 1.50∗∗∗ 45.8+− 1.85∗∗∗ 51.9+− 2.42∗∗∗†
CRP (mg/dl)§ 1.64+− 0.36 2.31+− 0.20∗∗∗ 2.36+− 0.26∗∗∗ 2.22+− 0.33∗∗∗
Table 2 Frequencies of the RANTES promoter − 28C>G and − 403G> A genotypes in all CAD patients, the subgroup of
patients with or without Type 2 diabetes and in healthy controls
CAD Patients
Controls All Without Type 2 With Type 2
(n = 416) (n = 553) diabetes (n = 377) diabetes (n = 176) P value compared with controls
n % n % n % n % All Without With
RANTES − 28C/G
CC 265 63.7 379 68.5 261 69.2 118 67.0
CG 135 32.5 162 29.3 108 28.6 54 30.7 0.143 0.150 0.538
GG 16 3.8 12 2.2 8 2.1 4 2.3
G allele frequency 167 20.1 186 16.8 124 16.4 62 17.6 0.074 0.069 0.376
RANTES − 403G/A
GG 135 32.5 229 41.4 154 40.8 75 42.6
GA 211 50.7 242 43.8 170 45.1 72 40.9 0.017 0.048 0.049
AA 70 16.8 82 14.8 53 14.1 29 16.5
A allele frequency 351 42.2 406 36.7 276 36.6 130 36.9 0.016 0.024 0.106
from those in controls (Table 2). However, the genotype
and allele frequencies of −28C>G SNP failed to reach
significance between controls and CAD patients.
The presence of the minor allele of the RANTES
−403G>A SNP was associated with a lower risk
of CAD [OR 0.68 (95% CI 0.52–0.89), P= 0.004].
The significance of the association remained after
adjustments for age, BMI, cigarette smoking and alcohol
consumption [OR 0.70 (95% CI 0.54–0.92), P= 0.011]
(Table 3). Moreover, this association was independent
of diabetes status (results not shown). With regard to
the −28C>G polymorphism, there was no difference
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Table 3 Unadjusted and adjusted OR for all CAD patients according to the RANTES − 28C>G and − 403G> A promoter
genotype
The adjusted OR is tested by logistic regression with adjustment for age, BMI, cigarette smoking and alcohol consumption. ‡ indicates reference.
RANTES genotype Unadjusted OR (95 % CI) P value Adjusted OR (95 % CI) P value
− 28 C‡ compared with G 0.81 (0.64–1.02) 0.074 0.84 (0.66–1.06) 0.142
CC + CG‡ compared with GG 0.56 (0.26–1.19) 0.128 0.57 (0.26–1.26) 0.167
CC‡ compared with CG+ GG 0.81 (0.62–1.05) 0.115 0.84 (0.64–1.11) 0.225
− 403 G‡ compared with A 0.80 (0.66–0.96) 0.014 0.82 (0.68–0.99) 0.039
G/G+ G/A‡ compared with A/A 0.86 (0.61–1.22) 0.397 0.91 (0.64–1.30) 0.592
G/G‡ compared with G/A+ A/A 0.68 (0.52–0.89) 0.004 0.70 (0.54–0.92) 0.011
in CAD risk both in the dominant or recessive model
even after adjustment [CC+CGcomparedwithGG:OR
0.57 (95% CI 0.26–1.26), P= 0.167; CC compared with
CG+GG: OR 0.84 (95% CI 0.64–1.11), P= 0.225].
In the LD test, −28C>G and −403G>A had a
positive LD; however, r2 values were not considerably
high (r2 = 0.347). Also, the −28C>G polymorphism
failed to have any association with CAD risk, and
the −28C>G genotype-related phenotypes including
serum RANTES levels were not significantly different in
each of control or CAD patients, with or without LLD
treatment (results not shown). Thus we did not perform
further analysis on −28C>G polymorphism.
Clinical characteristics and circulating
levels of RANTES and CRP, and platelet
count, associated with the − 403G> A
polymorphism
There was a significant association between the serum
RANTES concentration and the−403G>Agenotype in
controls (G/G: 44.7+− 3.3 ng/ml, G/A: 36.5+− 2.0 ng/ml,
A/A: 28.7+− 2.5 ng/ml; P< 0.001), non-diabetic CAD
patients (G/G: 50.9+− 3.0 ng/ml, G/A: 42.2+− 2.6 ng/ml,
A/A: 41.3+− 4.4 ng/ml; P< 0.05) and diabetic CAD
patients (G/G: 58.5+− 3.5 ng/ml, G/A: 49.6+− 4.1 ng/ml,
A/A: 42.2+− 4.3 ng/ml; P< 0.05). Because of the role
of LLD treatment on the modification of inflam-
matory markers [8], we subdivided further the CAD
patients according to LLD treatment (Figure 1). Mean
concentrations of RANTES in CAD patients treated
with or without LLD were 49.0+− 2.01 ng/ml and
48.1+− 2.27 ng/ml respectively. However, the association
between the serum RANTES level and the −403G>A
genotype was different according to LLD treatment.
There was no difference in circulating levels of RANTES
across the genotype in CAD patients with LLD treat-
ment, whereas there was a significant association between
the serum RANTES concentrations and the −403G>A
genotype in untreated CAD patients, with A/A subjects
having values approx. 35% lower than G/G sub-
jects (P< 0.05) (Figure 1). TheRANTES levels in patients
carrying the −403A allele were unaffected by LLD
treatment; however, patients carrying the −403G/G
genotype in the LLD treatment group had approx.
15% lower concentrations of RANTES than those
in the non-LLD treatment group. This pattern was
shown regardless of their diabetic status. There were no
significant genotype-related differences among control
subjects according to their −403G>A SNP genotype
with respect to age, BMI, cigarette smoking, alcohol
consumption, serum glucose, insulin and lipid profiles
(results not shown). Similarly, in CAD patients, there
were no genotype-related differences for age, BMI,
cigarette smoking, alcohol consumption, serum glucose,
insulin, lipid profiles and pharmacological interventions
(results not shown). No significant genotype associations
with circulating levels of CRP and platelet count in
control subjects and CAD patients were observed
regardless of their LLD treatment status (results not
shown).
Correlation between RANTES, CRP and
platelet count
We found that serum RANTES levels were positively
correlated with CRP concentration (r= 0.289, P< 0.001)
and platelet count (r= 0.253, P< 0.001).
DISCUSSION
The major finding of the present study is that the
frequency of theRANTES−403A allelewas significantly
lower in patients with CAD regardless of the presence
of Type 2 diabetes. The lower concentrations of serum
RANTES in subjects carrying the AA genotype com-
paredwith those with theGG genotype could potentially
explain the apparent CAD protection associated with the
RANTES −403A allele. In addition, a beneficial effect
of LLD treatment on RANTES levels was observed
in patients carrying the −403G/G genotype. The main
biological role of RANTES, a CC chemokine, relates
to leucocyte chemoattraction. Although interactions
between circulating leucocytes and endothelium are
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Figure 1 Relationship between the RANTES − 403G> A genotype and serum RANTES concentration in healthy controls or
CAD patients with or without LLD treatment
Values are means+− S.E.M. #RANTES concentrations were log-transformed. ∗P < 0.05 compared with G/G and †P < 0.05 compared with G/A, as determined by
one-way ANOVA followed by Tukey’s test.
beneficial in the host defence mechanism against infec-
tion, HIV and cancer, these interactions may also induce
the initiation of arterial lesion formation [9,10]. This
mechanism is supported by findings showing impaired
T-cell and monocyte recruitment to inflammatory sites
in mice deficient in theRANTES gene [11]. Furthermore,
the RANTES antagonist Met-RANTES (an N-terminal-
modified methionylated form of RANTES) was found
to inhibit monocyte recruitment on carotid endothelium,
neointima formation and macrophage accumulation after
arterial injury, as well as atherosclerosis progression
in uninjured arteries in ApoE-deficient mice [3,12,13].
RANTES antagonists that have been tested in heart
transplantation [14] and HIV models [15] might also
prove effective in preventing CAD.
Three SNPs in the RANTES gene (−403G>A and
−28C>G in the promoter, and ln1.1T/C in the first
intron) have been reported in different studieswith regard
to the extent of RANTES expression [4–6]. One study [4]
showed that the ln1.1C allele strongly down-regulates the
transcriptional activity of RANTES, whereas the −28G
allele causes a modest up-regulation and the−403A allele
has no obvious effect on RANTES expression. Another
group [5] reported that the−403A allele resulted in an up
to 8-fold increase in constitutive transcriptional activity
after transient transfections of the human mast cell line
HMC-1 and the T-cell line Jurkat with reporter vectors
driven by either the mutant or wild-type RANTES
promoter. However, both studies [4,5] did not determine
the protein level of RANTES according to polymorphic
sites in the RANTES gene. These conflicting results may
come from the different experimental modelling, since
RANTES production may be time- and cell-dependent
even in the context of the same genetic background [5]. In
addition, considering the complex system of chemokines
and chemokine receptors, further studies determining
the association of the RANTES gene with the RANTES
receptor gene and other proximal genes are necessary in
order to confirm such genotype effects and the functional
significance of RANTES.
Clinical associations of the RANTES −403A allele
have been reported with several inflammatory diseases
[5,7,16–18]. The RANTES −403A allele has been
associated with an increased susceptibility to atopy
[5,16], asthma [16] and sarcoidosis [17] as well as
atherosclerosis [7,18], suggesting RANTES is a candidate
gene for predisposing to inflammatory diseases. Recently,
Zhernakova et al. [19] reported that the −403A allele
was associated with a lower serum level of RANTES,
providing further protection from Type 1 diabetes.
Also, Boger et al. [20] showed that individuals with the
−403A allele, which is in almost complete LD with
the ln1.1C allele, would be low-expressors of RANTES.
These results corroborate the present observations of the
association of the −403A allele with a low concentration
of serum RANTES and consequently with a reduced
CAD risk. However, the RANTES −28C>G promoter
polymorphism had no association with CAD risk and no
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genotype-related phenotype differences in the present
study.
Overall, the lower concentration of serum RANTES
observed in Korean men with the −403A allele was
associated with a significantly lower CAD risk (30%)
even after adjustment for age, BMI, cigarette smoking and
alcohol consumption. However, the present findings are
in contrast with a previous study in a White population,
which reported an association of the RANTES −403A
allele with an increased CAD risk [7]. This discrepancy
could be attributed to ethnic differences; interestingly,
this allele is at a much higher frequency in Koreans
(approx. 0.42) compared with Caucasians (approx. 0.17),
which may reflect some positive selection in favour of
this allele involving differential susceptibility for the
environmental changes [21]. Other differences between
the present study and that of Simeoni et al. [7] relates
to the population selection. Whereas the previous study
investigated cases of White men and women with a
mean age of 64 years undergoing coronary angiography
because of chest pain or non-invasive tests consistent
with MI, the population in the present study consisted
of Korean men aged 40–65 years old. This selection was
made based on the knowledge that CAD is greatly
influenced by genetic factors at younger ages (below
65 years) [22]. Furthermore, differences existed between
the clinical phenotypes (i.e. CAD with angiographic
abnormalities and acute coronary syndrome compared
with CAD, including ∼50% myocardial infarct and
∼50% coronary angiography defined atherosclerosis) in
both studies.
A hyperglycaemic state has been suggested to increase
the secretion of cytokines and, in turn, cytokines
stimulate the expression of RANTES [23,24]. In the
present study, CAD patients with Type 2 diabetes had
higher concentrations of serumRANTES comparedwith
those without diabetes. On the other hand, CADpatients
carrying the −403G/G genotype in the LLD treatment
group had an approx. 15% lower concentration
of RANTES than those in the non-LLD treat-
ment group regardless of the presence of Type 2 diabetes.
This finding suggests a beneficial effect of LLD treatment
on RANTES concentrations since the proportions of
antihypertensive and antiplatelet therapieswere not signi-
ficantly different between LLD and non-LLD treatment
groups. Indeed statins, the most common LLD treat-
ment used by patients in the present study, is known to
have both a lipid-lowering effect and anti-inflammatory
properties [8]. Interestingly, patients carrying the
RANTES −403A allele had no differences in
serum RANTES concentrations between subjects
taking or not taking LLDs. Therefore we suggest a
pharmacogenetic effect associated with LLD treatment
with the RANTES polymorphism, with G/G subjects
getting additional benefit beyond their lipid-lowering
effect.
RANTES stored in platelet secretory vesicles is
released upon platelet activation and immobilized on
the surface of inflamed endothelium [10,25]. In the
present study, despite the positive relationship between
platelet concentrations and RANTES levels, the lack of
association between the RANTES−403G>A polymor-
phism and platelet levels indicate that the genotype
effects on serum RANTES may not be related to platelet
concentrations. RANTES has been suggested to activate
the transcription of cytokines genes [11,26] which
can activate hepatic synthesis of CRP. Although there
was no significant association between the RANTES
−403G>A polymorphism and circulating CRP levels,
we observed a positive relationship between serum
RANTES and pro-inflammatory CRP levels.
Several points should be considered when interpreting
the present findings. First, current methods of measuring
circulating RANTES levels in serum would not exclude
the possibility of enhanced RANTES concentrations due
to ex vivo platelet release during sample processing.
Relevant to this limitation, the report that circulating
RANTES levels does not correlate with local RANTES
levels at a site of tissue damage has to be considered
[27]. Secondly, our results share the limitations of
cross-sectional observational studies by which we only
evaluated association rather than prospective prediction.
Thirdly, although the present results showed that the
RANTES −403A allele is associated with CAD risk,
the frequency of the subjects carrying the A/A
homozygous genotype or G allele was not significantly
different between control and CAD patients. How-
ever, different frequencies of each G/A genotype and
G/G genotype between CAD patients and controls
would contribute to the relationship of the RANTES
−403G>A polymorphism and CAD risk. Finally,
because gender is an important risk factor forCAD, in the
present study we specifically focused on a representative
group of Korean men aged 40–65 years. Therefore our
results cannot be generalized towomenor to other ethnic,
age or geographical groups. Despite these limitations,
our results show an interesting association between the
RANTES −403A allele and reduced risk of CAD as well
as a potential pharmacogenomic interaction between this
allele and some of the pleiotropic effects of lipid-lowering
medication.
ACKNOWLEDGMENTS
This work was funded by KOSEF (Korea Science
and Engineering Foundation), the Korean Government
Ministry of Science & Technology (M10642120002-
06N4212-00210), National Research Laboratory project
#2005-01572 (Ministry of Science & Technology, Seoul,
South Korea), Korea Health 21 R&D Projects, Ministry
of Health & Welfare, Seoul, South Korea (A000385,
C© The Authors Journal compilation C© 2007 Biochemical Society
356 Y. Jang and others
A020593), Korea Research Foundation grant, the Korea
Government (MOEHRD, Basic Research Promotion
Fund) (KRF-2006-311-C00640), NIH (National In-
stitutes of Health)/NHLBI (National Heart, Lung
and Blood Institute) grant number HL54776, and
contracts 53-K06-5-10 and 58-1950-9-001 from the U.S.
Department of Agriculture Research Service, Beltsville,
Maryland, U.S.A.
REFERENCES
1 Libby, P. (2002) Inflammation in atherosclerosis.
Nature 420, 868–874
2 Cocchi, F., Devico, A. L., Garzino-Demo, A., Arya, S. K.,
Gallo, R. C. and Lusso, P. (1995) Identification of
RANTES, MIP-1α, and MIP-1β as the major
HIV-suppressive factors produced by CD8+ T cells.
Science 270, 1811–1815
3 Veillard, N. R., Kwak, B., Pelli, G. et al. (2004) Antagonism
of RANTES receptors reduces atherosclerotic plaque
formation in mice. Circ. Res. 94, 253–261
4 An, P., Nelson, G. W., Wang, L. et al. (2002)
Modulating influence on HIV/AIDS by interacting
RANTES gene variants. Proc. Natl. Acad. Sci. U.S.A. 99,
10002–10007
5 Nickel, R. G., Casolaro, V., Wahn, U. et al. (2000) Atopic
dermatitis is associated with a functional mutation in the
promoter of the C-C chemokine RANTES. J. Immunol.
164, 1612–1616
6 McDermott, D. H., Beecroft, M. J., Kleeberger, C. A. et al.
(2000) Chemokine RANTES promoter polymorphism
affects risk of both HIV infection and disease progression
in the Multicenter AIDS Cohort Study. AIDS 14,
2671–2678
7 Simeoni, E., Winkelmann, B. R., Hoffmann, M. M. et al.
(2004) Association of RANTES G-403A gene
polymorphism with increased risk of coronary
arteriosclerosis. Eur. Heart J. 25, 1438–1446
8 Waehre, T., Damas, J. K., Gullestad, L. et al. (2003)
Hydroxymethylglutaryl coenzyme a reductase inhibitors
down-regulate chemokines and chemokine receptors in
patients with coronary artery disease. J. Am. Coll. Cardiol.
41, 1460–1467
9 Hansson, G. K. (2001) Immune mechanisms in
atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21,
1876–1890
10 Stemme, S., Faber, B., Holm, J., Wiklund, O., Witztum,
J. L. and Hansson, G. K. (1995) T lymphocytes from
human atherosclerotic plaques recognize oxidized
low-density lipoprotein. Proc. Natl. Acad. Sci. U.S.A. 92,
3893–3897
11 Makino, Y., Cook, D. N., Smithies, O. et al. (2002)
Impaired T cell function in RANTES-deficient mice.
Clin. Immunol. 102, 302–309
12 Von Hundelshausen, P., Weber, K. S. C., Huo, Y. et al.
(2005) RANTES deposition by platelets triggers monocyte
arrest on inflamed and atherosclerotic endothelium.
Circulation 103, 1772–1777
13 Weyrich, A. S., Elstad, M. R., McEver, R. P. et al. (1996)
Activated platelets signal chemokine synthesis by human
monocytes. J. Clin. Invest. 97, 1525–1534
14 Horuk, R., Clayberger, C., Krensky, A. M. et al. (2001) A
non-peptide functional antagonist of the CCR1 chemokine
receptor is effective in rat heart transplant rejection.
J. Biol. Chem. 276, 4199–4204
15 Strizki, J. M., Xu, S., Wagner, N. E., Wojcik, L. et al. (2001)
SCH-C (SCH 351125), an orally bioavailable, small
molecule antagonist of the chemokine receptor CCR5, is a
potent inhibitor of HIV-1 infection in vitro and in vivo.
Proc. Natl. Acad. Sci. U.S.A. 98, 12718–12723
16 Fryer, A. A., Spiteri, M. A., Bianco, A. et al. (2000) The
−403 G>A promoter polymorphism in the RANTES
gene is associated with atopy and asthma. Genes Immun. 1,
509–514
17 Takada, T., Suzuki, E., Ishida, T. et al. (2001) Polymorphism
in RANTES chemokine promoter affects extent of
sarcoidosis in Japanese. Tissue Antigens 58, 293–298
18 Szalai, C., Duba, J., Prohaszka, Z. et al. (2001) Involvement
of polymorphisms in the chemokine system in the
susceptibility for coronary artery disease (CAD):
coincidence of elevated Lp(a) and MCP-1 −2518 G/G
genotype in CAD patients. Atherosclerosis 158, 233–239
19 Zhernakova, A., Alizadeh, B. Z., Eerligh, P. et al. (2006)
Genetic variants of RANTES are associated with serum
RANTES level and protection for type 1 diabetes.
Genes Immun. 7, 544–549
20 Boger, C. A., Fischereder, M., Deinzer, M. et al. (2005)
RANTES gene polymorphisms predict all-cause and
cardiac mortality in Type 2 diabetes mellitus hemodialysis
patients. Atherosclerosis 183, 121–129
21 Sabeti, P. C., Schaffner, S. F., Fry, B. et al. (2006) Positive
natural selection in the human lineage. Science 312,
1614–1620
22 Marenberg, M. E., Risch, N., Berkman, L. F., Floderus, B.
and de Faire, U. (1994) Genetic susceptibility to death
from coronary heart disease in a study of twins.
N. Eng. J. Med. 330, 1041–1046
23 Satriano, J. A., Banas, B., Luckow, B., Nelson, P., Krensky,
A. M. and Schlondorff, D. O. (1997) Regulation of
RANTES and ICAM-1 expression in murine mesangial
cells. J. Am. Soc. Nephrol. 8, 596–603
24 Schwarz, M., Radeke, H. H., Resch, K. and
Uciechowski, P. (1997) Lymphocyte-derived cytokines
induce sequential expression of mono-human mesangial
cells. Kidney Int. 52, 1521–1531
25 Weyrich, A. S., Prescott, S. M. and Zimmermann, G. A.
(2002) Platelets, endothelial cells, inflammatory
chemokines, and restenosis. Circulation 106, 1433–1435
26 Locati, M., Deuschle, U., Massardi, M. L. et al. (2002)
Analysis of the gene expression profile activated by the CC
chemokine ligand 5/RANTES and by lipopolysaccharide
in human monocytes. J. Immunol. 168, 3557–3562
27 Gallo, R. C., Garzino-Demo, A. and DeVico, A. L. (1999)
HIV infection and pathogenesis: what about chemokines?
J. Clin. Immunol. 19, 293–299
Received 8 January 2007/2 May 2007; accepted 15 May 2007
Published as Immediate Publication 15 May 2007, doi:10.1042/CS20070014
C© The Authors Journal compilation C© 2007 Biochemical Society
